Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its P/E ratio of 29, which is significantly higher than its peers, such as PTC Therapeutics, Inc. with a P/E of 5.85 and Harmony Biosciences Holdings, Inc. at 11.40. Additionally, Supernus has an EV to EBITDA ratio of 9.02, which also suggests a premium compared to its industry counterparts.
In terms of performance, Supernus has shown strong returns, with a year-to-date return of 38.74% compared to the S&P 500's 13.30%, and a one-year return of 48.26% against the S&P 500's 14.08%. This outperformance may reflect investor optimism, but the high valuation ratios indicate that the stock may not be sustainable at these levels. Overall, Supernus Pharmaceuticals, Inc. is currently overvalued.